The US Patent and Trademark Office (USPTO) has issued a notice of patent allowance for DelMar Pharmaceuticals’ first-in-class small-molecule chemotherapeutic VAL-083.
The patent covers the methods for synthesizing VAL-083, which is presently being assessed in Phase I/II trial in the US to treat glioblastoma multiforme (GBM).
DelMar Pharma president and CEO Jeffrey Bacha said, "In pre-clinical and clinical studies by the U.S. National Cancer Institute, VAL-083 has been shown to be safe and effective in fighting a range of tumor types, including glioblastoma multiforme, the most common and aggressive form of brain cancer."
Patent applications claim compositions and methods of using VAL-083 and related compounds in addition to methods of synthesis and quality controls for the manufacturing process of VAL-083.
Additionally, VAL-083 is protected under the Orphan Drug Act by the FDA and by the European Committee for Orphan Medical Products.
